Aspire Biopharma Files 8-K/A Amendment
Ticker: ASBP · Form: 8-K/A · Filed: Apr 17, 2026
Sentiment: neutral
Topics: amendment, corporate-governance, material-agreement
TL;DR
Aspire Biopharma just amended its 8-K filing, likely changing bylaws or agreements. Keep an eye on this.
AI Summary
Aspire Biopharma Holdings, Inc. filed an amendment (8-K/A) on April 17, 2026, to its previous filing. This amendment pertains to Item 1.01 (Entry into a Material Definitive Agreement) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), indicating changes or updates to significant agreements and corporate governance documents. The filing also includes Item 9.01 (Financial Statements and Exhibits).
Why It Matters
This amendment suggests that Aspire Biopharma Holdings, Inc. is making significant updates to its corporate structure or entering into new material agreements, which could impact its business operations and future strategy.
Risk Assessment
Risk Level: medium — Amendments to material definitive agreements or bylaws can signal significant shifts in a company's operations or financial standing, warranting closer scrutiny.
Key Players & Entities
- Aspire Biopharma Holdings, Inc. (company) — Filer of the 8-K/A
- 0001847345 (company) — CIK number for Aspire Biopharma Holdings, Inc.
- 2026-04-17 (date) — Filing date of the 8-K/A
- 2026-04-15 (date) — Period of report for the 8-K/A
FAQ
What specific material definitive agreement was entered into or amended, as indicated by Item 1.01?
The filing does not provide specific details of the material definitive agreement in the provided text; it only indicates that Item 1.01 is relevant to the amendment.
What changes were made to Aspire Biopharma's Articles of Incorporation or Bylaws, as per Item 5.03?
The provided text for the 8-K/A filing does not detail the specific amendments made to the Articles of Incorporation or Bylaws under Item 5.03.
What is the purpose of filing an amendment (8-K/A) on April 17, 2026?
The amendment is filed to update or correct information previously reported in an 8-K filing, specifically concerning Item 1.01 and Item 5.03.
Are there any new financial statements or exhibits included with this amended filing?
Yes, Item 9.01 indicates that Financial Statements and Exhibits are part of this filing, and the document list includes various exhibit types like EX-3.1 and XBRL files.
What is the business address and contact information for Aspire Biopharma Holdings, Inc.?
The business address is 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928, and the phone number is 561-704-8527.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on April 17, 2026 regarding Aspire Biopharma Holdings, Inc. (ASBP).